COVID-19 NEWS: Neutralizing antibody activity against all variants of #SARS-CoV-2, including Delta, lasted 6 months in people who got 2 doses of #COVID19 mRNA #vaccine. Findings online now @ScienceMagazine bit.ly/3fY1BEs #NIAID, @EmoryMedicine researchers used multiple tests to measure different types of antibody response and whether they functioned against new virus variants.

COVID-19 NEWS: A new analysis of data (not yet peer-reviewed) from the Moderna #COVID19 vaccine Ph 3 trial adds evidence toward establishing a "correlate of protection"—a measurable marker of efficacy used to predict whether a vaccine will be protective bit.ly/CoP1273 The data indicate levels of neutralizing antibody responses strongly correlate with protection against symptomatic COVID-19. 4 kinds of tests showed that higher antibody levels correlated with higher estimated vaccine efficacy against symptomatic COVID-19.

NIAID investigators and collaborators at @ImmunoScape and @JHUcovidplasma recently published a study in @jclinicalinvest characterizing #Tcell responses in people who recover from #SARSCoV2 infection. jci.org/articles/view/… T cells are a type of white blood cell part of the immune system & may allow for long-term protection against #SARSCoV2. Learning more about natural infection can help guide development of improved treatments and vaccines.